Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma

Olatz Zenarruzabeitia; Joana Vitallé; Itziar Astigarraga; Francisco Borrego

doi:10.1158/1078-0432.CCR-16-2478

Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma

Clin Cancer Res. 2017 Feb 1;23(3):615-617. doi: 10.1158/1078-0432.CCR-16-2478. Epub 2016 Nov 21.

Authors

Olatz Zenarruzabeitia¹, Joana Vitallé¹, Itziar Astigarraga^{2

3

4}, Francisco Borrego^{5

6

7}

Affiliations

¹ Immunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
² Pediatric Oncology Group, BioCruces Health Research Institute, Barakaldo, Spain.
³ Pediatrics Service, Cruces University Hospital, Barakaldo, Spain.
⁴ Department of Pediatrics, Faculty of Medicine and Dentistry, University of the Basque Country, Leioa, Spain.
⁵ Immunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain. francisco.borregorabasco@osakidetza.eus.
⁶ Immunotherapy Group, Center for Transfusion and Human Tissues, Galdakao, Spain.
⁷ Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

PMID: 27872101
DOI: 10.1158/1078-0432.CCR-16-2478

Abstract

TGFβ in the tumor microenvironment diminishes natural killer (NK) cell-mediated anti-disialoganglioside (anti-GD2) mAb elimination of neuroblastoma cells. Consequently, blockade of TGFβ signaling with galunisertib in combination with the anti-GD2 mAb dinutuximab plus adoptively transferred NK cells is a promising tool for the treatment of neuroblastoma. Clin Cancer Res; 23(3); 615-7. ©2016 AACRSee related article by Tran et al., p. 804.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Humans
Killer Cells, Natural / immunology
Neuroblastoma / immunology*
Pyrazoles
Quinolines
Tumor Microenvironment

Substances

Antibodies, Monoclonal
Pyrazoles
Quinolines
LY-2157299
dinutuximab